These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

538 related items for PubMed ID: 27385022

  • 1. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
    Hanatani A, Shibata A, Kitada R, Iwata S, Matsumura Y, Doi A, Sugioka K, Takagi M, Yoshiyama M.
    Heart Vessels; 2017 Mar; 32(3):287-294. PubMed ID: 27385022
    [Abstract] [Full Text] [Related]

  • 2. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
    Tominaga N, Kida K, Matsumoto N, Akashi YJ, Miyake F, Kimura K, Shibagaki Y.
    Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
    [Abstract] [Full Text] [Related]

  • 3. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
    Gheorghiade M, Gattis WA, O'Connor CM, Adams KF, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C, Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators.
    JAMA; 2004 Apr 28; 291(16):1963-71. PubMed ID: 15113814
    [Abstract] [Full Text] [Related]

  • 4. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC.
    Am J Physiol Renal Physiol; 2006 Feb 28; 290(2):F273-8. PubMed ID: 16189291
    [Abstract] [Full Text] [Related]

  • 5. Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics.
    Nakamura M, Sunagawa O, Kinugawa K.
    Int Heart J; 2018 Feb 28; 59(1):87-93. PubMed ID: 29375117
    [Abstract] [Full Text] [Related]

  • 6. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S, Mitsuda T, Miura A, Imai R, Iwamiya S, Ozaki Y, Kato T, Miura T, Watarai M, Murohara T.
    Heart Vessels; 2016 Oct 28; 31(10):1643-9. PubMed ID: 26615607
    [Abstract] [Full Text] [Related]

  • 7. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
    Tominaga N, Kida K, Inomata T, Sato N, Izumi T, Akashi YJ, Shibagaki Y.
    Am J Nephrol; 2017 Oct 28; 46(5):417-426. PubMed ID: 29130954
    [Abstract] [Full Text] [Related]

  • 8. The Efficacy of Tolvaptan in Congestive Heart Failure Patients with and Without Hypoalbuminemia: A Pilot Study.
    Okabe T, Yakushiji T, Igawa W, Ono M, Kido T, Ebara S, Yamashita K, Yamamoto MH, Saito S, Hoshimoto K, Amemiya K, Isomura N, Araki H, Ochiai M.
    Cardiovasc Ther; 2015 Oct 28; 33(5):275-81. PubMed ID: 26122275
    [Abstract] [Full Text] [Related]

  • 9. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y.
    Cardiovasc Drugs Ther; 2011 Dec 28; 25 Suppl 1():S67-76. PubMed ID: 22120095
    [Abstract] [Full Text] [Related]

  • 10. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
    Katsumata M, Hirawa N, Sumida K, Kagimoto M, Ehara Y, Okuyama Y, Fujita M, Fujiwara A, Kobayashi M, Kobayashi Y, Yamamoto Y, Saka S, Yatsu K, Fujikawa T, Toya Y, Yasuda G, Tamura K, Umemura S.
    Clin Exp Nephrol; 2017 Oct 28; 21(5):858-865. PubMed ID: 28190113
    [Abstract] [Full Text] [Related]

  • 11. Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction.
    Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR.
    J Card Fail; 2016 Jun 28; 22(6):423-32. PubMed ID: 26915749
    [Abstract] [Full Text] [Related]

  • 12. Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure.
    Matsukawa R, Kubota T, Okabe M, Yamamoto Y.
    Heart Vessels; 2016 Oct 28; 31(10):1650-8. PubMed ID: 26676672
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
    Matsuzaki M, Hori M, Izumi T, Fukunami M, Tolvaptan Investigators.
    Cardiovasc Drugs Ther; 2011 Dec 28; 25 Suppl 1():S33-45. PubMed ID: 22120092
    [Abstract] [Full Text] [Related]

  • 14. Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR.
    Ikeda Y, Inomata T, Kida K, Shibagaki Y, Sato N, Izumi T, Ako J, Kanagawa Aquaresis Investigators.
    Heart Vessels; 2019 Mar 28; 34(3):442-451. PubMed ID: 30259172
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics: a phase III open-label study.
    Fukunami M, Matsuzaki M, Hori M, Izumi T, Tolvaptan Investigators.
    Cardiovasc Drugs Ther; 2011 Dec 28; 25 Suppl 1():S47-56. PubMed ID: 22120093
    [Abstract] [Full Text] [Related]

  • 16. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R, Ciccarelli A, Ariano C, Cioppa C, Giasi A, Pucciarelli A, Cantatrione S.
    Minerva Cardioangiol; 2011 Dec 28; 59(6):543-54. PubMed ID: 21330961
    [Abstract] [Full Text] [Related]

  • 17. Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin.
    Kadota M, Ise T, Yagi S, Iwase T, Akaike M, Ueno R, Kawabata Y, Hara T, Ogasawara K, Bando M, Bando S, Matsuura T, Yamaguchi K, Yamada H, Soeki T, Wakatsuki T, Sata M.
    Int Heart J; 2016 Jul 27; 57(4):461-5. PubMed ID: 27357439
    [Abstract] [Full Text] [Related]

  • 18. The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery.
    Kato TS, Nakamura H, Murata M, Kuroda K, Suzuki H, Yokoyama Y, Shimada A, Matsushita S, Yamamoto T, Amano A.
    BMC Cardiovasc Disord; 2016 Sep 13; 16(1):181. PubMed ID: 27624603
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.
    Vaduganathan M, Gheorghiade M, Pang PS, Konstam MA, Zannad F, Swedberg K, Grinfeld L, Burnett JC, Krasa HB, Zimmer C, Blair J, Ouyang J, Maggioni AP, EVEREST investigators.
    J Cardiovasc Med (Hagerstown); 2012 Jul 13; 13(7):415-22. PubMed ID: 22673023
    [Abstract] [Full Text] [Related]

  • 20. The efficacy of tolvaptan as a diuretic for chronic kidney disease patients.
    Tanaka A, Katsuno T, Ozaki T, Sakata F, Kato N, Suzuki Y, Kosugi T, Kato S, Tsuboi N, Sato W, Yasuda Y, Mizuno M, Ito Y, Matsuo S, Maruyama S.
    Acta Cardiol; 2015 Apr 13; 70(2):217-23. PubMed ID: 26148383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.